IBJNews

Biosciences institute aims for $300M endowment

Back to TopCommentsE-mailPrintBookmark and Share

The effort to launch a life sciences research institute in Indianapolis got $25 million from the Legislature, but the life sciences institutions backing the effort have set their funding sights much higher.

The Indiana Biosciences Research Institute would build up an endowment of $300 million to $400 million over the next five to seven years, under a plan developed by Gov. Mike Pence’s staff, the life sciences group BioCrossroads and a steering committee of life sciences institutions.

Those institutions include Indianapolis-based Eli Lilly and Co., Indianapolis-based Dow AgroSciences LLC, Bloomington-based Cook Group Inc., the state’s research universities and other companies.

The endowment, which would be drawn from corporate and philanthropic sources, would fund annual operations of the institute and help recruit world-class scientists. The most likely focus of the research is diabetes and metabolic diseases.

“We had an amazing response from Indiana’s key life sciences companies,” said Ryan Streeter, Pence’s economic policy adviser. He added, “We’re pretty confident that everybody involved can contribute” to reach the endowment goal.

Pence first touted the idea of the institute in August when he was campaigning to be governor. It was one of several ideas generated earlier in 2012 by meetings convened by BioCrossroads to discuss what should be Indiana’s next step to advance its life sciences industry.

In October, Lilly CEO John Lechleiter embraced the institute idea in a speech at a BioCrossroads conference.

Then in January, Streeter and BioCrossroads CEO David Johnson started working with life sciences companies to flesh out a plan.

They will announce details of that plan in the next month or two, Streeter said. At that time, the board will be named, and then the board will start searching for a founding executive.

An executive with both science and business credentials is the most likely candidate at this point, Streeter said.

The basic idea of the institute is for it to be a place where scientists from both academia and industry collaborate, with a strong emphasis toward innovations that can be commercialized into products, procedures or new companies.

BioCrossroads’ Johnson said he expects the institute to name about five scientists to be principal investigators, who will then oversee the work of other researchers. Total staff could be 50 to 200, he speculated.

However many people work for the institute, they would not likely be all gathered under one roof. Johnson said much of the work would happen virtually. Still, the institute likely will have a physical presence in Indianapolis, although that location has yet to be determined.

Indiana is “late to the party” in starting an applied research institute focused on life sciences, noted a January 2013 report by BioCrossroads. There are similar institutes in Cambridge, Mass.; Chevy Chase, Md.; Kansas City, Mo.; La Jolla, Calif.; Orlando, Fla.; Phoenix; San Diego; and in other cities.

Most of those institutes were started with huge philanthropic donations and sustain themselves with a mix of industry and government research funding.

The Indiana Bioscience Research Institute hopes to do something that has yet to be done: launch an institute primarily based on corporate support. The idea is to use the corporate-funded endowment to sustain the institute, and then attract talented researchers that compete successfully for government and industry research grants.

Johnson argues that is the only way to fund an institute these days. Federal research funding has been stagnant for years and doesn’t appear to be headed up any time soon. Meanwhile, he noted, large life sciences companies—especially pharmaceutical firms—have been cutting back on their internal R&D spending and are looking more and more to essentially outsource the work to universities and applied research institutes.

“The life sciences industry is not being rewarded today by investors in the stock market for in-house research,” Johnson said. He added, “That research is going to come from the academic bench or the institution bench, which is going to be bigger than the in-house bench at many life sciences companies. The institute is going to stand in the middle of that.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. If I were a developer I would be looking at the Fountain Square and Fletcher Place neighborhoods instead of Broad Ripple. I would avoid the dysfunctional BRVA with all of their headaches. It's like deciding between a Blackberry or an iPhone 5s smartphone. BR is greatly in need of updates. It has become stale and outdated. Whereas Fountain Square, Fletcher Place and Mass Ave have become the "new" Broad Ripples. Every time I see people on the strip in BR on the weekend I want to ask them, "How is it you are not familiar with Fountain Square or Mass Ave? You have choices and you choose BR?" Long vacant storefronts like the old Scholar's Inn Bake House and ZA, both on prominent corners, hurt the village's image. Many business on the strip could use updated facades. Cigarette butt covered sidewalks and graffiti covered walls don't help either. The whole strip just looks like it needs to be power washed. I know there is more to the BRV than the 700-1100 blocks of Broad Ripple Ave, but that is what people see when they think of BR. It will always be a nice place live, but is quickly becoming a not-so-nice place to visit.

  2. I sure hope so and would gladly join a law suit against them. They flat out rob people and their little punk scam artist telephone losers actually enjoy it. I would love to run into one of them some day!!

  3. Biggest scam ever!! Took 307 out of my bank ac count. Never received a single call! They prey on new small business and flat out rob them! Do not sign up with these thieves. I filed a complaint with the ftc. I suggest doing the same ic they robbed you too.

  4. Woohoo! We're #200!!! Absolutely disgusting. Bring on the congestion. Indianapolis NEEDS it.

  5. So Westfield invested about $30M in developing Grand Park and attendance to date is good enough that local hotel can't meet the demand. Carmel invested $180M in the Palladium - which generates zero hotel demand for its casino acts. Which Mayor made the better decision?

ADVERTISEMENT